Condition

Minimal Residual Disease clinical trials and research

• 21Clinical trials
• 13NIH research projects
• 3New in 30 days
• 8Countries

Newest Minimal Residual Disease clinical trials

All recruiting trials (21)

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer

  A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.

  Recruiting Masaryk Memorial Cancer Institute · Brno, Czech Republic · NCT07895459

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• Multi-omics blood and CT monitoring for early detection of lung cancer recurrence after neoadjuvant therapy and surgery

  This project tests whether combining blood-based multi-omics (metabolomics and cfDNA), CT radiomics, and AI can noninvasively detect early recurrence after surgery in NSCLC patients treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07291921

• New method for monitoring lung cancer after surgery

  This study is testing a new way to monitor lung cancer after surgery using blood tests to see if it helps patients stay cancer-free longer compared to standard methods.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06930807

• Infusion of specialized immune cells for patients with acute myeloid leukemia

  This study is testing whether infusing special immune cells from a matched donor can help adults with acute myeloid leukemia who are in remission but still have some remaining cancer cells.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT06885476

• Combining PD-1 inhibitor with venetoclax for treating tough cases of leukemia and myelodysplastic syndromes

  This study is testing a new treatment that combines three drugs to see if it can help people with tough cases of leukemia and myelodysplastic syndromes who haven't responded to other treatments.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing, Beijing Municipality · NCT06536959

• Comparing stem cell transplant and non-transplant treatments in multiple myeloma patients

  This study is testing whether a stem cell transplant works better than other treatments for multiple myeloma patients who have very low levels of the disease after their initial therapy.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06463717

• French testing of blood-based ctDNA to find leftover cancer after surgery in Stage III colorectal cancer

  We will test whether blood-based ctDNA can find leftover cancer after surgery in people with Stage III colorectal cancer to help guide additional treatment.

  Recruiting University Hospital, Montpellier · Montpellier, Hérault · NCT06287814

• French test of leftover tumor DNA in the blood after pancreatic cancer surgery

  This will test whether a blood test for tumor DNA after surgery or after adjuvant chemotherapy can find pancreatic cancer patients at high risk of relapse.

  Recruiting University Hospital, Montpellier · Montpellier, Hérault · NCT06287749

• ctDNA blood tests to guide treatment in colorectal cancer with liver metastases

  A study using blood tests that look for tumor DNA to help decide which patients with colorectal cancer that has spread to the liver need more treatment after surgery.

  Recruiting at 2 sites University Hospital, Montpellier · Montpellier and 1 other locations · NCT06287723

• Using ctDNA to monitor treatment response in triple-negative breast cancer

  This study is testing if checking for cancer DNA in the blood can help doctors see how well treatment is working for people with triple-negative breast cancer after they receive chemotherapy.

  Recruiting at 14 sites Personalis Inc. · Tucson, Arizona and 13 other locations · NCT06230185

• Combining Chidamide and Azacitidine for AML Treatment After Transplant

  This study is testing if combining two drugs, Chidamide and azacitidine, can help people with acute myeloid leukemia who still have some cancer after a stem cell transplant to stay cancer-free longer.

  Recruiting Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT06066905

• Treatment of adult acute lymphoblastic leukemia with a pediatric regimen in Brazil

  This study is testing a children's leukemia treatment plan to see if it can help adults in Brazil with a specific type of leukemia live longer and have fewer health problems.

  Recruiting Instituto do Cancer do Estado de São Paulo · São Paulo, São Paulo · NCT05959720

• Assessing minimal residual disease in esophageal cancer patients

  This study is testing how treatment affects leftover cancer cells in patients with advanced esophageal cancer to see if it helps predict how well the treatment is working.

  Recruiting Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT05952661

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• T cell receptor depletion for blood cancer treatment

  This study is testing a new way to treat blood cancers by using a special treatment before a stem cell transplant to see if it helps both kids and adults do better after the procedure.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05735717

• Predicting treatment outcomes and recurrence risk in high-risk GIST patients using liquid biopsy

  This study is trying to see if analyzing blood samples for tumor DNA can help doctors predict treatment success and the chance of cancer coming back in patients with high-risk gastrointestinal stromal tumors.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT05408897

• Improving leukemia diagnosis using artificial intelligence

  This study is testing whether an artificial intelligence system can improve the diagnosis of leukemia by comparing its accuracy and speed to traditional methods using a large set of blood samples.

  Recruiting Munich Leukemia Laboratory · Munich, Bavaria · NCT04466059

• HA-1 TCR T cell therapy for leukemia that returned or didn't respond after a donor stem cell transplant

  This Phase 1 study will test whether giving specially engineered donor T cells called HA-1 TCR T cells is safe and what dose works for people whose acute leukemia came back or didn't respond after a donor stem cell transplant.

  Recruiting Phase 1 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03326921

• A biorepository for cancer research and precision medicine

  This study is collecting and storing samples from cancer patients to help researchers find better treatments and improve care for people with cancer.

  Recruiting at 38 sites Caris Science, Inc. · Mobile, Alabama and 37 other locations · NCT01499394

NIH-funded research (13)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Targeting minimal residual disease in AML with smart imaging and AI

  A patient-centered project to find better ways to treat residual leukemia cells after remission using advanced imaging and AI together with precise measurement tools.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11404887

• Postoperative ctDNA in Drain Fluid to Detect Remaining Cancer in Head and Neck Cancer

  A patient-friendly test using fluid from surgical drains after head and neck cancer surgery may reveal tiny remaining cancer cells sooner.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11402625

• Finding and targeting tiny leftover colon cancer cells after surgery

  This project will collect hidden cancer cells from patients after colon cancer surgery, grow them in the lab, and test drugs to try to stop the cancer from coming back.

  NIH research Duke University · Durham, United States · NIH-11278760

• Better blood tests to find tiny leftover cancer

  This project is testing ultra-sensitive blood tests to find tiny amounts of cancer DNA in people treated for breast and other cancers.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11225122

• Orphan noncoding RNA test to detect buried cancer cells in lung cancer

  A new blood test using orphan noncoding RNAs and AI aims to find tiny amounts of residual lung cancer after surgery to guide subsequent treatment.

  NIH research Exai Bio, INC. · Palo Alto, United States · NIH-11192382

• Spotting and targeting leftover AML cells with AI and single-cell tools

  This project uses AI-powered imaging and single-cell measurements to find treatments that could stop relapse in people with AML who are in remission but still have tiny amounts of disease.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11189593

• Understanding why lung cancer treatments stop working

  This work aims to understand why some lung cancer cells survive targeted treatments, leading to drug resistance in patients.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11117158

• A new T-cell treatment for acute myeloid leukemia after transplant

  This project explores a new T-cell treatment designed to prevent acute myeloid leukemia from returning in people who have had a stem cell transplant.

  NIH research Marker Therapeutics, INC. · Houston, United States · NIH-11042150

• A new test to detect leftover cancer cells in lung cancer patients after surgery

  This study is testing a new way to find tiny amounts of leftover cancer cells in people with non-small cell lung cancer after surgery, using a special blood test that looks at unique RNA from tumors, so doctors can better tailor treatments for you.

  NIH research Exai Bio, INC. · Palo Alto, United States · NIH-11008417

• Tracking minimal residual disease in cancer using advanced blood tests

  This study is looking at new ways to find tiny amounts of cancer cells in the blood, which could help patients get better early detection, track how well their treatment is working, and adjust their care if needed.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-10994176

• Creating a highly sensitive test for detecting leftover leukemia cells in patients with Acute Myeloid Leukemia.

  This study is testing a new blood test that uses advanced technology to better find tiny amounts of leftover leukemia cells in patients with Acute Myeloid Leukemia, helping doctors create more personalized treatment plans and reduce the chance of relapse.

  NIH research Twinstrand Biosciences, INC. · Seattle, United States · NIH-10907583

• Using advanced imaging and AI to target leftover cancer cells in acute myeloid leukemia

  This study is looking to help people with acute myeloid leukemia (AML) by finding and targeting any leftover cancer cells after their first round of chemotherapy, using advanced imaging and smart technology to create personalized treatment plans that could stop the cancer from coming back.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-10878458

• Understanding how certain signals contribute to persistent cancer cells in lung cancer models

  This study is looking at how certain genetic changes in lung cancer can affect how well treatments work, using special models to understand why some cancer cells might survive even after therapy, which could help create better treatments for patients in the future.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10872298

Related topics

Quick answers

How many Minimal Residual Disease clinical trials are recruiting right now?

21, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 8 countries. The most sites are in China (8 trials), United States (5 trials), France (3 trials), Brazil (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2, Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →